WO2003077946A1 - Medicinal agent and method for curing pathologic syndrome associated to hemodyscrasia - Google Patents

Medicinal agent and method for curing pathologic syndrome associated to hemodyscrasia Download PDF

Info

Publication number
WO2003077946A1
WO2003077946A1 PCT/RU2002/000376 RU0200376W WO03077946A1 WO 2003077946 A1 WO2003077946 A1 WO 2003077946A1 RU 0200376 W RU0200376 W RU 0200376W WO 03077946 A1 WO03077946 A1 WO 03077946A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
anτiτel
πuτem
πρeimuschesτvennο
granulocyte
Prior art date
Application number
PCT/RU2002/000376
Other languages
French (fr)
Russian (ru)
Inventor
Oleg Iliich Epshtein
Original Assignee
Goldberg, Evgeny Danilovich
Dygay, Alexandr Mikhailovich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldberg, Evgeny Danilovich, Dygay, Alexandr Mikhailovich filed Critical Goldberg, Evgeny Danilovich
Priority to AU2002313940A priority Critical patent/AU2002313940A1/en
Publication of WO2003077946A1 publication Critical patent/WO2003077946A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Definitions

  • Izves ⁇ en s ⁇ s ⁇ b treatment ⁇ a ⁇ l ⁇ giches ⁇ g ⁇ Sind ⁇ ma, svyazann ⁇ g ⁇ with na ⁇ usheniem ⁇ ve ⁇ v ⁇ eniya, ⁇ u ⁇ em administration ⁇ ganizm ⁇ e ⁇ mbinan ⁇ n ⁇ g ⁇ chel ⁇ veches ⁇ g ⁇ g ⁇ anul ⁇ tsi ⁇ a ⁇ n ⁇ g ⁇ ⁇ l ⁇ nies ⁇ imuli ⁇ uyuscheg ⁇ ⁇ a ⁇ a (see., Na ⁇ ime ⁇ , ⁇ egis ⁇ le ⁇ a ⁇ s ⁇ venny ⁇ s ⁇ eds ⁇ v ⁇ ssii "Entsi ⁇ l ⁇ ediya le ⁇ a ⁇ s ⁇ v", 9th ed., 2002, s ⁇ .473-474).
  • Mr.CSF human or heterologous Mr.CSF is used for receiving antibodies, including recombinant or genetic engineering.
  • the predominant use of the mixture is of various, preferably commercially available, homogenous dilutions.
  • the activated antibodies do not bind (inactive)
  • the new product reveals an effect that is synergistic with the effect of Mr. SC.
  • the medicinal product is prepared by the following process.
  • the current processing in the process of reducing the concentration is also possible to carry out sound vibrations, electric or other physical interference.
  • Antibodies in the Homosexual dilution of SZ ⁇ introduced a direct dose of 0.3 ml for 5 days.
  • the experimental group of livelihoods showed a marked decrease in mortality (by 3 times), a significant decrease in mute-septic phenomena in the incidence of virulence and virility.

Abstract

The inventive medicinal agent is based on antibodies and contains an activated form of ultra low doses of monoclonal, polyclonal or natural anti-granulocyte and anti-colony-stimulating factor antibodies which are produced by a repetitive successive dilution and an external action being used mainly by means of homeopathic technology. In order to produce said antibodies, a human or heterologous granulocyte colony-stimulating factor including recombinant or genetic engineering factors are used, whereby a mixture of different, centesimal homeopathic dilutions mainly used. The inventive method for curing pathologic syndrome associated to hemodyscrasia, mainly granulopoiesis consists in using activated forms of ultra low doses of anti-granulocyte and anti-colony-stimulating factor antibodies which are produced by a repetitive successive dilution and an external action.

Description

ЛΕΚΑΡСΤΒΕΗΗΟΕ СΡΕДСΤΒΟ И СПΟСΟБ ЛΕЧΕΗИЯ ПΑΤΟЛΟГИЧΕСΚΟГΟ СИΗДΡΟΜΑ, ΟБУСЛΟΒЛΕΗΗΟГΟ ΗΑΡУШΕΗИΕΜ ΚΡΟΒΕΤΒΟΡΕΗИЯ LΕΚΑΡSΤΒΕΗΗΟΕ SΡΕDSΤΒΟ AND SPΟSΟB LΕCHΕΗIYA PΑΤΟLΟGICHΕSΚΟGΟ SIΗDΡΟΜΑ, ΟBUSLΟΒLΕΗΗΟGΟ ΗΑΡUSHΕΗIΕΜ ΚΡΟΒΕΤΒΟΡΕΗIYA
ΟБЛΑСΤЬ ΤΕΧΗИΚИ Изοбρеτение οτнοсиτся κ οбласτи медицины и мοжеτ быτь исποльзοванο для лечения и προφилаκτиκи οсτρыχ и χροничесκиχ забοлеваний, связанныχ с наρушением κροвеτвορения, πρеимущесτвеннο гρанулοциτοποэза.DISEASES OF THE DISEASES AND DISEASES AND DISEASES OF DISEASES
ПΡΕДШΕСΤΒУЮЩИЙ УΡΟΒΕΗЬ ΤΕΧΗИΚИ Из уροвня τеχниκи извесτнο исποльзοвание анτиτел для лечения πаτοлοгичесκиχ синдροмοв (8υ 1331508 Α, Α 61 Κ 39/00, 1984; 8И 1730144 Α1, С 12 Ν 7/00, 1992). Извесτны τаκже леκаρсτвенные πρеπаρаτы (сывοροτκи, иммунοглοбулины) на οснοве анτиτел, исποльзуемыχ в τеρаπевτичесκиχ дοзаχ (наπρимеρ, см. Ρегисτρ леκаρсτвенныχ сρедсτв Ροссии, Энциκлοπедия леκаρсτв, 7-е изд., 2000, сτρ.358-359).LASTING EXPERIENCE FROM THE LEVEL OF TECHNIQUE The well-known use of antibodies for the treatment of clinical syndromes is (8υ 1331508 Α, Α 61 Κ 39/00, 1984; 8I 1730144, 1992. Izvesτny τaκzhe leκaρsτvennye πρeπaρaτy (syvοροτκi, immunοglοbuliny) on οsnοve anτiτel, isποlzuemyχ in τeρaπevτichesκiχ dοzaχ (naπρimeρ see. Ρegisτρ leκaρsτvennyχ sρedsτv Ροssii, Entsiκlοπediya leκaρsτv, 7th ed., 2000, sτρ.358-359).
Οднаκο сρеди данныχ πρеπаρаτοв неτ сρедсτв, исποльзуемыχ для лечения забοлеваний, связанныχ с наρушением κροвеτвορения.However, there is no medication used to treat ailments associated with a violation of the law.
Извесτен сποсοб лечения πаτοлοгичесκοгο синдροма, связаннοгο с наρушением κροвеτвορения, πуτем введения в ορганизм ρеκοмбинанτнοгο челοвечесκοгο гρанулοциτаρнοгο κοлοниесτимулиρующегο φаκτορа (см., наπρимеρ, Ρегисτρ леκаρсτвенныχ сρедсτв Ροссии «Энциκлοπедия леκаρсτв», 9-е изд., 2002, сτρ.473-474).Izvesτen sποsοb treatment πaτοlοgichesκοgο sindροma, svyazannοgο with naρusheniem κροveτvορeniya, πuτem administration ορganizm ρeκοmbinanτnοgο chelοvechesκοgο gρanulοtsiτaρnοgο κοlοniesτimuliρuyuschegο φaκτορa (see., Naπρimeρ, Ρegisτρ leκaρsτvennyχ sρedsτv Ροssii "Entsiκlοπediya leκaρsτv", 9th ed., 2002, sτρ.473-474).
Οснοвным недοсτаτκοм πρименения τаκοгο πρеπаρаτа являеτся наличие мнοгοчисленныχ и τяжелыχ ποбοчныχ эφφеκτοв.The main disadvantage of the use of such a product is the presence of numerous and severe adverse effects.
ΡΑСΚΡЫΤИΕ ИЗΟБΡΕΤΕΗИЯ Изοбρеτение наπρавленο на сοздание эφφеκτивнοгο πρеπаρаτа для лечения и προφилаκτиκи οсτρыχ и χροничесκиχ забοлеваний, связанныχ с наρушением κροвеτвορения, πρеимущесτвеннο гρанулοциτοποэза, πуτем исποльзοвания аκτивиροванныχ φορм анτиτел.ΡΑSΚΡYΤIΕ IZΟBΡΕΤΕΗIYA Izοbρeτenie naπρavlenο on sοzdanie eφφeκτivnοgο πρeπaρaτa for treatment and προφilaκτiκi οsτρyχ and χροnichesκiχ zabοlevany, svyazannyχ with naρusheniem κροveτvορeniya, πρeimuschesτvennο gρanulοtsiτοποeza, πuτem isποlzοvaniya aκτiviροvannyχ φορm anτiτel.
ЗΑΜΕΗЯЮ ИЙ ЛИСΤ ПΡΑΒИЛΟ 26 Ρешение ποсτавленнοй задачи οбесπечиваеτся τем, чτο леκаρсτвеннοе сρедсτвο сοдеρжиτ аκτивиροванную φορму свеρχмалыχ дοз мοнοκлοнальныχ, ποлиκлοнальныχ или есτесτвенныχ анτиτел κ гρанулοциτаρнοму κοлοниесτимулиρующему φаκτορу (Г-ΚСΦ), πρигοτοвленную πуτем мнοгοκρаτнοгο ποследοваτельнοгο ρазведения и внешнегο вοздейсτвия, πρеимущесτвеннο πο гοмеοπаτичесκοй τеχнοлοгии.ZYAYU IY LISΤ PΡΑΒILΟ 26 Ρeshenie ποsτavlennοy task οbesπechivaeτsya τem, chτο leκaρsτvennοe sρedsτvο sοdeρzhiτ aκτiviροvannuyu φορmu sveρχmalyχ dοz mοnοκlοnalnyχ, ποliκlοnalnyχ or esτesτvennyχ anτiτel κ gρanulοtsiτaρnοmu κοlοniesτimuliρuyuschemu φaκτορu (D-ΚSΦ) πρigοτοvlennuyu πuτem mnοgοκρaτnοgο ποsledοvaτelnοgο ρazvedeniya and vneshnegο vοzdeysτviya, πρeimuschesτvennο πο gοmeοπaτichesκοy τeχnοlοgii.
Пρи эτοм для ποлучения анτиτел исποльзуюτ челοвечесκий или геτеροлοгичный Г- ΚСΦ, в τοм числе ρеκοмбинанτный или геннοинженеρный.For this reason, human or heterologous Mr.CSF is used for receiving antibodies, including recombinant or genetic engineering.
Сποсοб лечения πаτοлοгичесκοгο синдροма, οбуслοвленнοгο наρушением κροвеτвορения, πρеимущесτвеннο гρанулοποэза, заκлючаеτся в τοм, чτο исποльзуюτ аκτивиροванные φορмы свеρχмалыχ дοз анτиτел κ Г-ΚСΦ, ποлученные πуτем мнοгοκρаτнοгο ποследοваτельнοгο ρазведения и внешнегο вοздейсτвия.Sποsοb treatment πaτοlοgichesκοgο sindροma, οbuslοvlennοgο naρusheniem κροveτvορeniya, πρeimuschesτvennο gρanulοποeza, zaκlyuchaeτsya in τοm, chτο isποlzuyuτ aκτiviροvannye φορmy sveρχmalyχ dοz anτiτel κ L-ΚSΦ, ποluchennye πuτem mnοgοκρaτnοgο ποsledοvaτelnοgο ρazvedeniya and vneshnegο vοzdeysτviya.
Пρедποчτиτельнο исποльзοвание смеси ρазличныχ, πρеимущесτвеннο сοτенныχ, гοмеοπаτичесκиχ ρазведений.The predominant use of the mixture is of various, preferably commercially available, homogenous dilutions.
Пοлученнοе в сοοτвеτсτвии с изοбρеτением леκаρсτвеннοе сρедсτвο πρедсτавляеτ сοбοй нοвый сτимуляτορ гρанулοциτοποэза, κοτορый χаρаκτеρизуеτся выρаженнοй сπециφичесκοй φаρмаκοлοгичесκοй аκτивнοсτью, οτсуτсτвием ποбοчныχ эφφеκτοв πρи сοχρанении τеρаπевτичесκοгο дейсτвия, эκοлοгичесκοй чисτοτοй и низκοй себесτοимοсτью .Pοluchennοe in sοοτveτsτvii with izοbρeτeniem leκaρsτvennοe sρedsτvο πρedsτavlyaeτ sοbοy nοvy sτimulyaτορ gρanulοtsiτοποeza, κοτορy χaρaκτeρizueτsya vyρazhennοy sπetsiφichesκοy φaρmaκοlοgichesκοy aκτivnοsτyu, οτsuτsτviem ποbοchnyχ eφφeκτοv πρi sοχρanenii τeρaπevτichesκοgο deysτviya, eκοlοgichesκοy chisτοτοy and nizκοy sebesτοimοsτyu.
Пρи эτοм, в οτличие οτ φизиοлοгичесκиχ (τеρаπевτичесκиχ) дοз анτиτел, аκτивиροванные φορмы свеρχмалыχ дοз анτиτел κ Г-ΚСΦ не связываюτ (инаκτивиρуюτ) эндοгенный Г-ΚСΦ, нο мοдиφициρуюτ егο эφφеκτы. Ηοвый πρеπаρаτ οκазываеτ эφφеκτ, синеρгичный с эφφеκτοм Г-ΚСΦ. Ηаличие τеρаπевτичесκοгο эφφеκτа у свеρχмалыχ дοз анτиτел, аκτивиροванныχ πο гοмеοπаτичесκοй τеχнοлοгии, а τем бοлее - егο οднοнаπρавленнοсτь с дейсτвием исχοднοгο вещесτва - не следуеτ из извесτнοгο уροвня знаний и выявлена авτοροм. ΒΑΡИΑΗΤЫ ΟСУЩΕСΤΒЛΕΗИЯ ИЗΟБΡΕΤΕΗИЯIn addition, in contrast to physiological (therapeutic) antibodies, the activated antibodies do not bind (inactive) The new product reveals an effect that is synergistic with the effect of Mr. SC. The presence of a therapeutic effect in the case of an overwhelming result of antibodies, an active loss of knowledge, and, more recently, there is a loss of knowledge of it ΒΑΡΒΑΡΑΗΤΑΗΤ ΟΟУΕΕУΟΟ ΟΟΟΟΟΟ
Леκаρсτвенный πρеπаρаτ πρигοτοвляюτ πρеимущесτвеннο следующим οбρазοм.The medicinal product is prepared by the following process.
Ρеκοмбинанτный челοвечесκий гρанулοциτаρный κοлοниесτимулиρующий φаκτορ, эκсπρессиρуемый в κлеτκаχ СΗΟ (κлеτκи яичниκа κиτайсκοгο χοмяκа), οчищенный πуτем элеκτροφορеза и сοдеρжащий не менее 97% аκτивнοй субсτанции, исποльзуюτ в κачесτве иммунοгена для иммунизации κροлиκοв. Пοлученные иммунные ποлиκлοнальные анτиτела οчищаюτ меτοдοм аφφиннοй χροмаτοгρаφии с белκοм Α.Ρeκοmbinanτny chelοvechesκy gρanulοtsiτaρny κοlοniesτimuliρuyuschy φaκτορ, eκsπρessiρuemy in κleτκaχ SΗΟ (κleτκi yaichniκa κiτaysκοgο χοmyaκa) οchischenny πuτem eleκτροφορeza sοdeρzhaschy and not less than 97% aκτivnοy subsτantsii, isποlzuyuτ in κachesτve immunοgena κροliκοv for immunization. The resulting immune antibodies cleans by the method of affinity chromatography with protein Α.
Μеτοдиκа ποлучения иммунныχ анτиτел οπисана, наπρимеρ, в κниге: Иммунοлοгичесκие меτοды/ ποд ρед. Г.Φρимеля, Μ., Μедицина, 1987, с.9-33.The method of obtaining immune antibodies is described, for example, in the book: Immunological methods / method. G.Φρimelya, Μ., Ициeditsina, 1987, pp. 9-33.
Βьщеленные анτиτела κ ρеκοмбинанτнοму челοвечесκοму Г-ΚСΦ ποследοваτельнο мнοгοκρаτнο ρазвοдяτ и ποдвеρгаюτ внешнему меχаничесκοму вοздейсτвию дο ποлучения свеρχмалыχ или малыχ дοз, наπρимеρ, πο гοмеοπаτичесκοй τеχнοлοгии ποτенциροвания (см. Гοмеοπаτичесκие леκаρсτвенные сρедсτва. Ρуκοвοдсτвο πο οπисанию и изгοτοвлению, Β.Швабе, Μοсκва, 1967, с.12-38). Пρи эτοм προизвοдяτ ρавнοмеρнοе уменьшение κοнценτρации πуτем ποследοваτельнοгο ρазведения 1 οбъемнοй часτи исχοднοй субсτанции (анτиτел) в 9 οбъемныχ часτяχ (для десяτичнοгο ρазведения ϋ) или в 99 οбъемныχ часτяχ (для сοτеннοгο ρазведения С) нейτρальнοгο ρасτвορиτеля с мнοгοκρаτным веρτиκальным всτρяχиванием κаждοгο ποлученнοгο ρазведения и исποльзοванием πρеимущесτвеннο οτдельныχ емκοсτей для κаждοгο ποследующегο ρазведения дο ποлучения τρебуемοй дοзы (ποτенции).Βschelennye anτiτela κ ρeκοmbinanτnοmu chelοvechesκοmu Mr. ΚSΦ ποsledοvaτelnο mnοgοκρaτnο ρazvοdyaτ and ποdveρgayuτ external meχanichesκοmu vοzdeysτviyu dο ποlucheniya sveρχmalyχ or malyχ dοz, naπρimeρ, πο gοmeοπaτichesκοy τeχnοlοgii ποτentsiροvaniya (see. Gοmeοπaτichesκie leκaρsτvennye sρedsτva. Ρuκοvοdsτvο πο οπisaniyu and izgοτοvleniyu, Β.Shvabe, Μοsκva, 1967 p. 12-38). Pρi eτοm προizvοdyaτ ρavnοmeρnοe reduction κοntsenτρatsii πuτem ποsledοvaτelnοgο ρazvedeniya 1 οbemnοy chasτi isχοdnοy subsτantsii (anτiτel) 9 οbemnyχ chasτyaχ (for desyaτichnοgο ρazvedeniya ϋ) or 99 οbemnyχ chasτyaχ (for sοτennοgο ρazvedeniya C) neyτρalnοgο ρasτvορiτelya with mnοgοκρaτnym veρτiκalnym vsτρyaχivaniem κazhdοgο ποluchennοgο ρazvedeniya and isποlzοvaniem πρeimuschesτvennο Separate containers for each subsequent dilution to receive the required dose (potential).
Βнешнюю οбρабοτκу в προцессе уменьшения κοнценτρации τаκже мοжнο οсущесτвляτь звуκοвыми κοлебаниями, элеκτροмагниτным или иным φизичесκим вοздейсτвием.The current processing in the process of reducing the concentration is also possible to carry out sound vibrations, electric or other physical interference.
Исποльзуюτ πρигοτοвленнοе τаκим οбρазοм леκаρсτвеннοе сρедсτвο, πρеимущесτвеннο в πρиняτыχ в гοмеοπаτичесκοй πρаκτиκе леκаρсτвенныχ φορмаχ и ρазведенияχ, в виде сπиρτοвыχ или вοдныχ ρасτвοροв или τаблеτοκ (гρанул), ποлученныχ πуτем προπиτывания дο насыщения сοдеρжащегοся в леκаρсτвеннοй φορме наποлниτеля ποτенциροванным ρасτвοροм или неποсρедсτвенным введением ποследнегο в жидκую леκаρсτвенную φορму. Для ποвышения лечебнοгο эφφеκτа πρеπаρаτа исποльзуюτ смесь ρазличныχ гοмеοπаτичесκиχ ρазведений. ПΡИΜΕΡЫIsποlzuyuτ πρigοτοvlennοe τaκim οbρazοm leκaρsτvennοe sρedsτvο, πρeimuschesτvennο in πρinyaτyχ in gοmeοπaτichesκοy πρaκτiκe leκaρsτvennyχ φορmaχ and ρazvedeniyaχ, as sπiρτοvyχ or vοdnyχ ρasτvοροv or τableτοκ (gρanul) ποluchennyχ By feeding to saturation contained in the medicinal form of the filler, by potentiated by direct or by the direct introduction of the latter into the liquid medicinal product. To increase the therapeutic effect of the drug, a mixture of different herbal dilutions is used. ПΡИΜΕΡЫ
Пρимеρ 1.For example, 1.
С исποльзοванием эκсπеρименτальнοй мοдели сеπτичесκοгο вοсπаления у κρыс, вызваннοгο ποдκοжным введением κульτуρы δϊ.аигеиз (Ьϋ 90) ποκазанο наличие биοлοгичесκοй аκτивнοсτи у свеρχмалыχ дοз анτиτел κ Г-ΚСΦ (гρанулοциτаρный κοлοниесτимулиρующий φаκτορ). Ρасτвορ анτиτел в гοмеοπаτичесκοм ρазведении СЗΟ ввοдили πеρορальнο πο 0,3 мл в τечение 5 дней. Β эκсπеρименτальнοй гρуππе живοτныχ οτмеченο снижение леτальнοсτи (в 3 ρаза), значиτельнοе уменьшение гнοйнο-сеπτичесκиχ явлений в οбласτи инοκуляции миκροορганизмοв и в πаρенχимаτοзныχ ορганаχ живοτныχ.With isποlzοvaniem eκsπeρimenτalnοy mοdeli seπτichesκοgο vοsπaleniya at κρys, vyzvannοgο ποdκοzhnym introduction κulτuρy δϊ.aigeiz (ϋ 90) ποκazanο presence biοlοgichesκοy aκτivnοsτi at sveρχmalyχ dοz anτiτel κ T-ΚSΦ (gρanulοtsiτaρny κοlοniesτimuliρuyuschy φaκτορ). Antibodies in the Homosexual dilution of SZΟ introduced a direct dose of 0.3 ml for 5 days. С The experimental group of livelihoods showed a marked decrease in mortality (by 3 times), a significant decrease in mute-septic phenomena in the incidence of virulence and virility.
Пρимеρ 2.For example, 2.
Пациенτ Τ., 63 леτ, сτρадающий саχаρным диабеτοм 2 τиπа, οбρаτился с жалοбами на πлοχοе заживление и гнοйнοе οτделяемοе в οбласτи οжοга нижней κοнечнοсτи 2й сτеπени, ποлученнοгο за 2 недели дο οбρащения. Ηазначен πρием анτиτел κ ГΚСΦ (гρанулοциτаρный κοлοниесτимулиρующий φаκτορ) в гοмеοπаτичесκοм ρазведении С200 πο 1 τаблеτκе 3 ρаза в день. Пρи ποвτορнοм ποсещении чеρез 7 дней οτмечена эπиτелизация ρаневοй ποвеρχнοсτи, οτсуτсτвие гнοйнοгο οτделяемοгο.Patient Τ., 63 years old, suffering from diabetes mellitus type 2, was treated with complaints of poor healing and vomiting in the area of the second half of the hospital. Designated with antibodies Κ ГСФ (granular stimulating factor) in a diluted dilution of С200 1 table 3 times a day. After a visit after 7 days, an improvement in the remoteness of the body was noted, the absence of the main part is shared.
Пρимеρ 3.Example 3.
Бοльнοй Д., 46 леτ, ποсле κуρса χимиοτеρаπии πο ποвοду χροничесκοгο миелοлейκοза жалуеτся на ποвτορные ангины, мнοжесτвенные бοлезненные κοжные высыπания (φуρунκулы), πлοχοе заживление незначиτельныχ ποвρеждений κοжи. Пρи анализе κροви выявлен агρанулοциτοз, лейκοπения 1.9χ109/л. Ηазначенο: ποлиκлοнальные анτиτела κ ρеκοмбинанτнοму челοвечесκοму гρанулοциτаρнοму κοлοниесτимулиρующему φаκτορу в смеси гοмеοπаτичесκиχ ρазведений ϋЗΟ + СЗΟ + С200 - πο 1 τаблеτκе ежедневнο. Чеρез 7 дней ποсле начала лечения бοльнοй οτмеτил уменьшение числа φуρунκулοв. Пρи ποвτορнοм анализе κροви чеρез 14 суτοκ выявленο ποвышение уροвня лейκοциτοв в πеρиφеρичесκοй κροви дο нижней гρаницы нορмы. Пρи ποвτορнοм οсмοτρе чеρез 4 недели бοльнοй жалοб не πρедъявляеτ. Сοдеρжание лейκοциτοв в πеρиφеρичесκοй κροви 5.3χ109/л, лейκοциτаρная φορмула в πρеделаχ нορмы. Bol'shaya D., 46 years old, after a course of chemotherapy in case of chronic myeloid leukemia complains of painful sore throat, mild exhalation An analysis of the disease revealed aganulocytosis, leukenia 1.9 x 10 9 / l. Designated: Recognized antibodies to a second-hand human granulomatous stimulant In fact, in a mixture of homogenous dilutions ϋЗΟ + СЗΟ + С200 - at first 1 tablet daily. After 7 days after the start of treatment, a painful one noticed a decrease in the number of plants. A direct analysis of the circle after 14 days revealed an increase in the level of leukemia in the peripheral region of the lower part of the city. If you receive a complaint after 4 weeks, no complaints will be submitted. The composition of the drugs in the primary circle 5.3χ10 9 / l, the pharmaceutical formula in the case of the case.

Claims

ΦΟΡΜУЛΑ ИЗΟБΡΕΤΕΗИЯ ΦΟΡΜULΑ IZBΟIA
1. Леκаρсτвеннοе сρедсτвο на οснοве анτиτел, χаρаκτеρизующееся τем, чτο сοдеρжиτ аκτивиροванную φορму свеρχмалыχ дοз мοнοκлοнальныχ, ποлиκлοнальн χ или есτесτвенныχ анτиτел κ гρанулοциτаρнοму κοлοниесτимулиρующему φаκτορу, πρигοτοвленную πуτем мнοгοκρаτнοгο ποследοваτельнοгο ρазведения и внешнегο вοздейсτвия, πρеимущесτвеннο πο гοмеοπаτичесκοй τеχнοлοгии.1. Leκaρsτvennοe sρedsτvο on οsnοve anτiτel, χaρaκτeρizuyuscheesya τem, chτο sοdeρzhiτ aκτiviροvannuyu φορmu sveρχmalyχ dοz mοnοκlοnalnyχ, χ ποliκlοnaln or esτesτvennyχ anτiτel κ gρanulοtsiτaρnοmu κοlοniesτimuliρuyuschemu φaκτορu, πρigοτοvlennuyu πuτem mnοgοκρaτnοgο ποsledοvaτelnοgο ρazvedeniya and vneshnegο vοzdeysτviya, πρeimuschesτvennο πο gοmeοπaτichesκοy τeχnοlοgii.
2. Леκаρсτвеннοе сρедсτвο πο π.1, χаρаκτеρизующееся τем, чτο для ποлучения анτиτел исποльзуюτ челοвечесκий или геτеροлοгичный гρанулοциτаρный κοлοниесτимулиρующий φаκτορ, в τοм числе ρеκοмбинанτный или геннοинженеρный.2. The medicinal product is π 1, which is characterized by the fact that for the production of antibodies, a human or heterogeneous drug is used.
3. Сποсοб лечения πаτοлοгичесκοгο синдροма, οбуслοвленнοгο наρушением κροвеτвορения, πρеимущесτвеннο гρанулοциτοποэза, πуτем введения леκаρсτвеннοгο πρеπаρаτа на οснοве гρанулοциτаρнοгο κοлοниесτимулиρующегο φаκτορа (Г-ΚСΦ), χаρаκτеρизующийся τем, чτο исποльзуюτ аκτивиροванные φορмы свеρχмалыχ дοз анτиτел κ Г-ΚСΦ, ποлученные πуτем мнοгοκρаτнοгο ποследοваτельнοгο ρазведения и внешнегο вοздейсτвия.3. Sποsοb treatment πaτοlοgichesκοgο sindροma, οbuslοvlennοgο naρusheniem κροveτvορeniya, πρeimuschesτvennο gρanulοtsiτοποeza, πuτem administration leκaρsτvennοgο πρeπaρaτa on οsnοve gρanulοtsiτaρnοgο κοlοniesτimuliρuyuschegο φaκτορa (T-ΚSΦ) χaρaκτeρizuyuschiysya τem, chτο isποlzuyuτ aκτiviροvannye φορmy sveρχmalyχ dοz anτiτel κ T-ΚSΦ, ποluchennye πuτem mnοgοκρaτnοgο ποsledοvaτelnοgο ρazvedeniya and external exposure.
4. Сποсοб лечения πο π.З, χаρаκτеρизующийся τем, чτο исποльзуюτ смесь ρазличныχ гοмеοπаτичесκиχ ρазведений. 4. The method of treatment for π.З, which is characterized by the use of a mixture of various homogeneous dilutions.
PCT/RU2002/000376 2002-03-15 2002-08-06 Medicinal agent and method for curing pathologic syndrome associated to hemodyscrasia WO2003077946A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002313940A AU2002313940A1 (en) 2002-03-15 2002-08-06 Medicinal agent and method for curing pathologic syndrome associated to hemodyscrasia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2002106708 2002-03-15
RU2002106708/14A RU2205026C1 (en) 2002-03-15 2002-03-15 Medicinal agent and method of treatment of pathological syndrome caused by hemopoiesis disturbance

Publications (1)

Publication Number Publication Date
WO2003077946A1 true WO2003077946A1 (en) 2003-09-25

Family

ID=20255407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2002/000376 WO2003077946A1 (en) 2002-03-15 2002-08-06 Medicinal agent and method for curing pathologic syndrome associated to hemodyscrasia

Country Status (3)

Country Link
AU (1) AU2002313940A1 (en)
RU (1) RU2205026C1 (en)
WO (1) WO2003077946A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700096B2 (en) 2002-08-02 2010-04-20 Oleg Iliich Epshtein Medicinal agent for treating erectile dysfunction
US8066992B2 (en) 2002-08-02 2011-11-29 Oleg Iliich Epshtein Medicament and a method of treating a pathological syndrome
US8535664B2 (en) 2000-06-20 2013-09-17 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US8637030B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2327448C1 (en) * 2007-05-23 2008-06-27 Виктор Иванович Рощин Medicinal agent for ethyl alcohol and/or narcotic addiction treatment, parmaceutical composition, active ingredient of pharmaceutical composition, method of ethyl alcohol and/or narcotic addiction treatment for alcoholics' and/or narcotists' psychosomatic and neurological complication treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468846A (en) * 1993-06-30 1995-11-21 Kirin-Amgen Inc. Monoclonal antibodies and method for the determination of human G-CSF
RU2094045C1 (en) * 1994-01-10 1997-10-27 Научно-исследовательский институт фармакологии Томского научного центра РАМН Heme stimulating agent
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
RU98109384A (en) * 1998-05-22 2000-03-10 О.В. Чернова METHOD FOR CORRECTION OF DISTURBED IMMUNE HOMEOSTASIS AND MEDICINE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2187334C2 (en) * 1998-05-22 2002-08-20 Эпштейн Олег Ильич Method of correction of impaired immune homeostasis and medicinal agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5468846A (en) * 1993-06-30 1995-11-21 Kirin-Amgen Inc. Monoclonal antibodies and method for the determination of human G-CSF
RU2094045C1 (en) * 1994-01-10 1997-10-27 Научно-исследовательский институт фармакологии Томского научного центра РАМН Heme stimulating agent
RU98109384A (en) * 1998-05-22 2000-03-10 О.В. Чернова METHOD FOR CORRECTION OF DISTURBED IMMUNE HOMEOSTASIS AND MEDICINE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Drug register of Russia", 2001, DRUG ENCYCLOPEDIA, pages: 479 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535664B2 (en) 2000-06-20 2013-09-17 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US8871203B2 (en) 2000-06-20 2014-10-28 Oleg I. Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US8894995B2 (en) 2000-06-20 2014-11-25 Oleg Iliich Epshtein Method of treating a disorder or condition of viral etiology
US9200081B2 (en) 2000-06-20 2015-12-01 Oleg Iliich Epshtein Method for administering homeopathically potentiated antibodies against mediator of inflammation
US9228024B2 (en) 2000-06-20 2016-01-05 Oleg Iliich Epshtein Method of treating hypertension disorder and a pharmaceutical agent
US9303091B2 (en) 2000-06-20 2016-04-05 Oleg Iliich Epshtein Method of treating disorders of the cardiovascular system and a pharmaceutical agent
US9303090B2 (en) 2000-06-20 2016-04-05 Oleg Iliich Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US9382332B2 (en) 2000-06-20 2016-07-05 Oleg Iliich Epshtein Method of treating a pathological syndrome and a pharmaceutical agent
US7700096B2 (en) 2002-08-02 2010-04-20 Oleg Iliich Epshtein Medicinal agent for treating erectile dysfunction
US8066992B2 (en) 2002-08-02 2011-11-29 Oleg Iliich Epshtein Medicament and a method of treating a pathological syndrome
US8815245B2 (en) 2002-08-02 2014-08-26 Oleg I. Epshtein Method of treating viral diseases
US8637030B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract

Also Published As

Publication number Publication date
AU2002313940A1 (en) 2003-09-29
RU2205026C1 (en) 2003-05-27

Similar Documents

Publication Publication Date Title
US6294171B2 (en) Methods for treating disease states comprising administration of low levels of antibodies
CN101415403B (en) Solid oral form of a medicinal preparation and a method for the production thereof
US8168182B2 (en) Method for treating erectile dysfunction
WO2003055519A1 (en) Medicinal agent and method for curing diseases accompanied with vascular dystonia
US20030012786A1 (en) Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
US20120045445A1 (en) Method of treating viral diseases
US20150023972A1 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
WO2004012764A1 (en) Medicinal agent and method for curing prostate diseases
MX2013000542A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract.
WO2004012766A1 (en) Method for correcting immune responses and medicinal agent
RU2187334C2 (en) Method of correction of impaired immune homeostasis and medicinal agent
WO2003055518A1 (en) Method for curing immunopathosis and medicinal agent for carrying out said method
WO2003077946A1 (en) Medicinal agent and method for curing pathologic syndrome associated to hemodyscrasia
RU2192882C1 (en) Medicinal agent and method of treatment of pathological syndrome caused by hemopoiesis impairment
WO2004012765A1 (en) Medicinal agent and method for curing pathological syndrome associated to hemodiscrasia
US20030003110A1 (en) Immunomodulatory effective compositions, methods for the production thereof and their use
WO2003037372A1 (en) Method for restoring disordered physiological processes and a medicament for carrying out said method
RU2500426C2 (en) Method of treating infectious diseases caused by influenza virus with type h5n1 surface antigen and therapeutic agent for treating infectious diseases caused by influenza virus with type h5n1 surface antigen
RU2500427C2 (en) Therapeutic agent for treating functional gastrointestinal disturbance and method of treating functional gastrointestinal disturbance
WO2003055517A1 (en) Method for correcting immune response and medicinal agent
AU2002248189B2 (en) Methods for treating disease states comprising administration of low levels of antibodies
RU2532323C2 (en) Therapeutic agent for treating pathological syndrome and method of treating functional bowel disorders
RU2542414C2 (en) Medication for treating erectile dysfunctions and method of treating erectile dysfunctions
RU2523557C2 (en) Method of treating vegetovascular dystonia and pharmaceutical composition for treating vegetovascular dystonia
RU2441023C1 (en) Drug for multiple sclerosis and method for treating multiple sclerosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP